Article Details
Retrieved on: 2019-04-30 03:47:48
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>New York-based <b>Benchmark Capital</b> has invested 0.76% in Galectin Therapeutics, Inc. (NASDAQ:GALT). 14,068 are owned by Goldman Sachs Group ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here